[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tyra Biosciences, Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":199},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,74,85,116,158],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053332","phase-2-a-study-of-tyra-300-in-children-with-achondroplasia-beach301-100053332",false,"NCT06842355","A Study of TYRA-300 in Children With Achondroplasia: BEACH301","A Multicenter, Phase 2, Dose-Escalation\u002FDose-Expansion Study of TYRA-300 in Children With Achondroplasia With Open Growth Plates: BEACH301","Inclusion Criteria:\n\n* Aged 3 to 10 years old (inclusive) at the time of consent.\n* Informed consent provided by parent(s) or legal guardian(s). As study participants are less than 18 years old, participants are willing and able to provide written assent (where applicable and required).\n* Molecular diagnosis of achondroplasia (FGFR3 G380R).\n* Radiographically confirmed open growth plates at Screening, as determined by bone age X-ray.\n* Able to stand and ambulate independently.\n* Able to take oral medication.\n* Sentinel Safety Cohort only: aged 5 to 10 years old (inclusive).\n* Cohort 1 only: aged 3 to 10 years old (inclusive) and are naive to prior growth accelerating therapy.\n* Cohort 2 only: aged 3 to 10 years old (inclusive) and have received prior growth accelerating therapy.\n\nExclusion Criteria:\n\n* Presence or history of any concurrent disease or condition that would interfere with study participation, safety evaluations, or any uncontrolled or untreated condition that could impact pediatric growth.\n* Diagnosis of endocrine condition that alters calcium\u002Fphosphate homeostasis.\n* Prior limb lengthening surgery or planned or expected to have limb lengthening surgery while enrolled in the study.\n* Taking medications that are strong inhibitors or inducers of cytochrome P450 (Cyp) 3A4.\n* History or current evidence of corneal or retinal disorder\u002Fkeratopathy.\n* Presence of guided growth hardware\u002F8 plates. Planned or anticipated orthopedic surgeries.","ALL","3 Years","10 Years",{"count":20,"type":21},92,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.",[27],"Achondroplasia","RECRUITING","2026-07-09",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2025-03-04",{"date":36,"type":21},"2030-06",{"name":38,"class":39},"Tyra Biosciences, Inc","INDUSTRY",19,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100613389","phase-2-phase-2ab-efficacy-and-safety-of-dabogratinib-in-participants-with-low-grade-upper-tract-urothelial-carcinoma-100613389","NCT07265947","Phase 2A\u002FB Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma","A Phase 2A\u002FB, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants With Low Grade Upper Tract Urothelial Carcinoma (SURF303)","SURF303","1. Participants ≥ 18 years of age at the time of informed consent and willing and able to comply with all required study procedures\n2. Confirmed LOW RISK LG UTUC (both favorable and unfavorable) per AUA\n3. At least 5mm of marker lesion left behind\n4. Participants must have previous genomic report or archival\u002Ffresh tissue in addition to urine sample for retrospective genomic testing\n5. Identification of marker lesion(s) within 8 weeks prior to randomization (refer to Inclusion Criterion #2)\n6. If synchronous NMIBC, NMIBC must be fully resected and low-grade Ta or T1\n7. No prior BCG administration within 1 year of date of consent.\n8. No intravesical chemotherapy within 8 weeks prior to C1D1 (including UGN-101).\n9. No systemic chemotherapy within 3 months prior to C1D1\n10. ECOG 0-2\n11. Pathology consists of pure urothelial carcinoma\n12. Adequate bone marrow, liver, and renal function:\n\n    1. i. Absolute neutrophil count (ANC) ≥1,500\u002Fmm3 ii. Platelet count ≥75,000\u002Fmm3 iii. Hemoglobin ≥10.0 g\u002FdL\n    2. i. Total bilirubin ≤ ULN ii. Alanine aminotransferase (ALT) ≤ ULN iii. Aspartate aminotransferase (AST) ≤ ULN\n    3. Estimated glomerular filtration rate \\>60 mL\u002Fmin\n    4. Serum Phosphate level ≤ ULN prior to starting treatment\n    5. International normalized ratio (INR) ≤1.5 × ULN\n\nExclusion Criteria:\n\n1. Evidence or any features of high grade (HG) UTUC\n2. History of carcinoma in situ (CIS)\n3. History of prostatic urethral involvement\n4. Current or previous history of muscle invasive bladder cancer\n5. Current or previous history of lymph node positive and\u002For metastatic bladder cancer\n6. Evidence of squamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma or small cell of the bladder\n7. Currently receiving systemic cancer therapy (cytotoxic or immunotherapy)\n8. Current or prior history of pelvic external beam radiotherapy for bladder cancer\n9. Current or history of receiving a prior FGFR inhibitor\n10. Systemic immunotherapy within 6 months prior to randomization\n11. Treatment with an investigational agent within 30 days or 5 half-lives from randomization, whichever is shorter; compounds with an unknown half-life will be default to 30 days.\n12. Prior treatment with an intravesical or intracavitary agent within 8 weeks of C1D1.\n13. Current evidence of central serous retinopathy or retinal pigmented epithelial detachment of any grade at time of baseline examination.\n14. Requiring use of medications that are potential inhibitors or inducers of CYP3A (prohibited list of medications)","18 Years",{"count":51,"type":21},230,[24],"A Phase 2A\u002FB study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma",[55],"Low Grade Upper Tract Urothelial Carcinoma",[57,58,55,59,60,61,62,63,64],"Low-grade UTUC","Upper Tract Urothelial Carcinoma","FGFR Gene Amplification","FGFR Gene Alteration","FGFR Gene Alterations","FGFR3 Mutation","FGFR3 Mutations","FGFR3 Gene Fusions","2026-06-30",{"date":67,"type":32},"2026-07-02",{"date":69,"type":32},"2025-12-22",{"date":71,"type":21},"2030-11",{"name":38,"class":39},12,{"id":75,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":25,"conditions":78,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":83,"locationsCount":84},"100580826",{"count":20,"type":21},[24],[27],"2026-06-27",{"date":65,"type":32},{"date":34,"type":32},{"date":36,"type":21},{"name":38,"class":39},18,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},"100592611","phase-2-efficacy-and-safety-of-tyra-300-in-participants-with-fgfr3-altered-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer-100592611","NCT06995677","Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer","A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)","SURF302","Inclusion Criteria:\n\n* Participants age 18 and over of informed consent and willing and able to comply with all requires study procedures\n* Able to understand and given written informed consent\n* Participants with histologically confirmed low-grade NMIBC within 6 weeks prior to randomization with prior diagnostic biopsy\u002FTURBT to confirm stage and grade and with at least 3 mm and no more than 12 mm total (1\u002F2 a resectoscope loop to 2 loops, refer to Section 8.1.5) residual visible tumor as a marker lesion(s) left behind:\n\n  1. Ta low grade\n  2. T1 low grade\n* Participants must have intermediate risk NMIBC, defined as having any of the following characteristics (AUA Guidelines, 2024)\n\n  1. Recurrence within 1 year, LG Ta\n  2. Solitary LG Ta \\>3cm\n  3. LG Ta, multifocal\n  4. LG T1\n* Documented activating FGFR3 mutation or fusion (Appendix 4)\n* Have undergone bladder mapping and identification of visible marker lesion(s) within 6 weeks prior to randomization (refer to Inclusion Criterion #3)\n* No evidence of urothelial carcinoma of the upper urinary tract (confirmed by imaging) or prostatic urethra within 6 months of randomization\n* No prior BCG administration within 1 year of date of consent.\n* No intravesical chemotherapy within 8 weeks prior to C1D1.\n* ECOG 0-1\n* Pathology consistent with pure urothelial carcinoma; if mixed histology, ensure that at least 80% of the sample is urothelial\n* Adequate bone marrow, liver, and renal function:\n\n  b. Bone marrow function: i. Absolute neutrophil count (ANC) \\> or = 1,500\u002Fmm3 ii. Platelet count \\> or = 75,000\u002Fmm3 iii. \u002Fhemoglobin \\> or = 10.0 g\u002FdL e. Liver function: i.Total bilirubin \\\u003C or = ULN ii. Alanine aminotransferase (ALT) \\\u003C or = ULN iii. Aspartate aminotransferase (AST) \\\u003C or = ULN f. Renal function: i. estimated glomerular filtration rate \\>60 mL\u002Fmin calculated using the modification of diet in renal disease equation or CKD-EPI formula ii. Serum Phosphate level \\\u003C or = ULN prior to starting treatment g. Coagulation i. International normalized ratio (INR) \\\u003C or = 1.5 x ULN\n* Ability to swallow tablets\n* Participants (male and female) of child-bearing potential (including females who are post-menopausal for less than 1 year) must be willing to practice effective contraception while on treatment and be willing and able to continue contraception for 3 months (males) and 6 months (females) after the last dose of study treatment. Potential male participants should consider the potential impact of TYRA-300 on their ability to father a child and discuss options with the site study staff.\n* Potential participants who are positive for human immunodeficiency virus (HIV) must have a viral load below the limits of detection and on stable antiretroviral therapy for at least 3 months prior to C1D1. NOTE: some of the compounds in antiretroviral therapy may be on the prohibited medications list. Allowances will be made to ensure the participant's HIV treatment continues uninterrupted following a discussion with the Sponsor's medical monitor. A discussion of the impact of the antiretroviral therapy on TYRA- 300 needs to be discussed with the potential participant prior to C1D1.\n* Potential participants with chronic hepatitis B virus (HBV) infection with active disease should be on a suppressive antiviral therapy prior to C1D1.\n* Potential participants patients with a history of hepatitis C virus (HCV) infection should have completed curative antiviral treatment and must have a HCV viral load below the limit of quantification.\n* Potential participants with a history of HCV infection and on current treatment must have a HCV viral load below the limit of quantification\n\nExclusion Criteria:\n\n* Presence of tumor in ureter or prostatic urethra:\n* Current or previous history of muscle invasive bladder cancer\n* Current or previous history of lymph node positive and\u002For metastatic bladder cancer\n* Evidence of pure squamous cell carcinoma, pure adenocarcinoma or pure undifferentiated carcinoma of the bladder\n* Currently receiving systemic cancer therapy (cytotoxic, immunotherapy, targeted)\n* Currently receiving treatment with a prohibited therapy (refer to Section 6.7.1)\n* Current or prior history of pelvic external beam radiotherapy\n* Current or history of receiving a prior FGFR inhibitor\n* Systemic immunotherapy within 6 months prior to randomization\n* Treatment with an investigational agent within 30 days or 5 half-lives from randomization, whichever is shorter; compounds with an unknown half-life will default to the 30 days.\n* Prior treatment with an intravesical agent within 8 weeks prior to C1D1\n* Current ongoing toxicity from previous therapy\n* Had major surgery within 4 weeks prior to C1D1\n* Any reason that in the view of the investigator, would substantially impair the ability of the participant to comply with study procedures and\u002For risk to the participant (i.e., uncontrolled diabetes)\n* Females who are pregnant, breastfeeding or planning to become pregnant within 6 months after the last dose of TYRA-300 and males who plan to father a child while enrolled in this study or within 3 months after the last dose of TYRA-300\n* Has impaired wound healing capacity\n* Serum phosphate levels above the upper limit of normal during screening\n* Any ocular condition likely to increase the risk of eye toxicity\n* Current evidence of central serous retinopathy or retinal pigmented epithelial detachment of any grade at time of baseline examination.\n* History of or current uncontrolled cardiovascular disease\n* Gastrointestinal disorders that will affect oral administration or absorption of TYRA-300\n* Known history of HIV infection, or active hepatitis B or C\n* History of a second primary malignancy within 3 years of signing ICF, except for nonmelanoma skin cancer and cured and active surveillance malignancies (i.e., prostate, breast) .\n* Known allergy to TYRA-300 or any excipients of the formulated product\n* Participants taking strong inhibitors and\u002For inducers of CYP3A4 enzyme\n* History of prolonged QT syndrome or baseline heart rate-corrected QT interval using Fridericia formula (QTcF) interval \\>470 ms",{"count":94,"type":21},90,[24],"Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC",[98,59,61,99,100,64],"Low-grade NMIBC","FGFR3 Gene Alteration","FGFR3 Gene Mutation",[102,103,104,105,106],"FGFR3 gene alterations","FGFR3 gene mutations","FGFR3 gene fusions","FGFR3","Non-Muscle Invasive Bladder Cancer","2026-06-26",{"date":109,"type":32},"2026-06-29",{"date":111,"type":32},"2025-06-27",{"date":113,"type":21},"2028-09",{"name":38,"class":39},45,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":128,"conditions":129,"keywords":139,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":156,"locationsCount":157},"100586467","phase-1-safety-and-preliminary-anti-tumor-activity-of-tyra-430-in-advanced-hepatocellular-carcinoma-and-other-solid-tumors-with-activating-fgffgfr-pathway-aberrations-100586467","NCT06915753","Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF\u002FFGFR Pathway Aberrations","A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF\u002FFGFR Pathway Aberrations","SURF431","Key Inclusion Criteria:\n\nAll Patients:\n\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.\n* Adequate end organ function.\n* Ability to swallow oral formulations.\n* Ability to understand and willingness to sign the ICF.\n\nPart A:\n\n* Histologically confirmed locally advanced unresectable\u002Fmetastatic HCC or histologically confirmed advanced solid tumor with documented FGF\u002FFGFR pathway alterations\n* For participants with histologically confirmed locally advanced or metastatic HCC:\n\n  * Barcelona Clinic Liver Cancer (BCLC) stage B that is not eligible for locoregional therapy, or stage C.\n  * Child-Pugh Score class A\n* Must have previously received SOC appropriate for their tumor type. Any number of prior therapies, including FGFR inhibitors, are permitted.\n* Agree to provide archival tumor tissue no older than 2 years from the time of enrollment, if available. If an archived specimen is not available, a biopsy is not required.\n\nPart B, Cohort 1:\n\n* Histologically confirmed locally advanced\u002Fmetastatic HCC who have previously received standard of care.\n* Barcelona Clinic Liver Cancer (BCLC) stage B that is not eligible for locoregional therapy, or stage C.\n* Child-Pugh Score class A\n* Availability of an archival formalin-fixed paraffin-embedded (FFPE) tumor tissue specimen obtained ≤2 years prior to screening for submission to sponsor-designated central laboratory for FGF19 IHC testing.\n* At least 1 measurable lesion by RECIST v1.1.\n\nPart B, Cohort 2:\n\n* Histologically confirmed advanced solid tumor except FGFR3-altered urothelial carcinoma and primary central nervous system tumors who have previously received standard of care. Note: Participants with confirmed diagnosis of locally advanced or metastatic HCC are not eligible for Cohort 2.\n* Must have an eligible activating gain-of-function alteration in the FGFR3 or FGFR4 gene, or focal amplifications of FGF19\n* Archival tumor tissue biopsy specimen no older than 2 years from the time of enrollment, if available. If a tissue biopsy specimen is not available, a biopsy is not required.\n* At least 1 measurable lesion by RECIST v1.1.\n\nKey Exclusion Criteria:\n\nAll Patients:\n\n* Have disease that is suitable for local therapy administered with curative intent.\n* Have not recovered from reversible toxicity of prior anticancer therapy to \\\u003C Grade 1 or baseline (except toxicities that are not clinically significant or not expected to resolve, including but not limited to, alopecia, fatigue, skin discoloration, or Grade 1 neuropathy).\n* Have received the following anticancer therapy:\n\n  1. Any immunotherapy or other antibody therapy within 28 days prior to the first dose of the study drug.\n  2. A TKI \\\u003C 5 days or 5X the terminal Phase elimination half-lives, whichever is longer, prior to the first dose of TYRA-430.\n  3. Other systemic therapy not listed above \\\u003C 14 days prior to the first dose of the study drug.\n* Participant discontinued a prior anti-FGFR therapy due to significant toxicity, defined as hepatotoxicity ≥ Grade 3 or any Grade 4 toxicity according to CTCAE v5.0.\n* Has a serum phosphorus level \\> upper limit of normal (ULN) during screening that remains \\>ULN despite medical management.\n* History of or current uncontrolled cardiovascular disease.\n* Active, symptomatic, or untreated brain metastases.\n* Have a diagnosis of primary CNS malignancies.\n* Gastrointestinal disorders that will affect oral administration or absorption of TYRA-430.\n* Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.\n* Any reason that, in the view of investigator, would substantially impair the ability of the participant to comply with study procedures and increase the risk to the participant.\n\nPart B, Cohort 1:\n\n* Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.\n* Prior treatment with pan-FGFR inhibitors or FGFR4-selective inhibitors.\n\nPart B, Cohort 2:\n\n* Histologically confirmed locally advanced\u002Fmetastatic HCC.\n* Histologically confirmed urothelial cancer.",{"count":125,"type":21},100,[127],"PHASE1","A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF\u002FFGFR pathway aberrations, including locally advanced\u002Fmetastatic hepatocellular carcinoma and other advanced solid tumors.",[130,131,132,59,61,99,100,133,134,135,136,137,64,138],"Metastatic Hepatocellular Carcinoma","Solid Tumors","Solid Tumor, Adult","Advanced Solid Tumors","FGFR4 Gene Mutation","FGFR4 Gene Fusions","FGF19 Gene Amplification","FGF19 Gene Overexpression","Locally Advanced Unresectable Hepatocellular Carcinoma",[140,141,142,143,144,102,145,146,147,103,104,148,149],"Hepatocellular Carcinoma","metastatic cancer","solid tumors","FGF19 gene amplifications","FGFR4 gene alterations","FGF19 gene alterations","FGFR4 gene mutations","FGFR4 gene fusions","FGF19 gene overexpression","locally advanced unresectable cancer","2025-11-18",{"date":152,"type":32},"2025-11-20",{"date":154,"type":32},"2025-04-24",{"date":113,"type":21},{"name":38,"class":39},16,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":175,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":198},"100528436","phase-1-safety-and-anti-tumor-activity-of-tyra-200-in-advanced-cholangiocarcinoma-with-activating-fgfr2-gene-alterations-100528436","NCT06160752","Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations","A Multicenter, Open-label, First-in-Human Study of TYRA-200 in Advanced Intrahepatic Cholangiocarcinoma and Other Solid Tumors With Activating FGFR2 Gene Alterations (SURF-201)","SURF201","Inclusion Criteria:\n\nPhase 1 Part A\n\n* Men and women 18 years of age or older.\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.\n* Any histologically confirmed advanced solid tumor with FGFR\u002FFGF pathway alterations including FGFR gene mutations, fusions, and amplifications, as well as gene amplifications of FGFR ligands, who have exhausted or refused approved standard therapies.\n* Evaluable disease according to RECIST v1.1.\n\nPhase 1 Part B\n\n* Men and women 18 years of age or older.\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.\n* Histologically confirmed locally advanced\u002Fmetastatic intrahepatic cholangiocarcinoma with a previously identified FGFR2 gene mutation or rearrangement.\n* Must have received a prior FGFR inhibitor. Participants may have received more than 1 prior FGFR inhibitor.\n* Presence of an FGFR2 kinase domain mutation that confers resistance to previous\u002Fother FGFR inhibitors; resistance mutations should be identified by a US Food and Drug Administration authorized\u002Fapproved companion diagnostic or a Clinical Laboratory Improvement Amendments (CLIA) validated local test performed in a certified laboratory.\n* At least 1 measurable lesion by RECIST v1.1.\n\nExclusion Criteria:\n\n* Discontinued a prior anti-FGFR therapy due to significant toxicity, defined as hepatotoxicity ≥Grade 3 or any Grade 4 toxicity according to CTCAE v5.0.\n* Has a serum phosphorus level \\> upper limit of normal (ULN) during screening that remains \\>ULN despite medical management.\n* Any ocular condition likely to increase the risk of eye toxicity.\n* History of or current uncontrolled cardiovascular disease.\n* Active, symptomatic, or untreated brain metastases.\n* Gastrointestinal disorders that will affect oral administration or absorption of TYRA-200.\n* Females who are pregnant, breastfeeding, or planning to become pregnant and males who plan to father a child while enrolled in this study.",{"count":167,"type":21},40,[127],"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced\u002Fmetastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.",[171,172,173,174],"Locally Advanced Cholangiocarcinoma","Intrahepatic Cholangiocarcinoma","Solid Tumor","Metastatic Cholangiocarcinoma",[176,177,178,179,180,181,182,183,184,141,142,185,186,187,188,189],"FGFR2 gene activation","FGFR2 gene alterations","FGFR2 gene fusion\u002Frearrangement","FGFR2 gene mutation","FGFR2 gene translocation","FGFR2","Fibroblast growth factor receptor 2 (FGFR2)","Fibroblast growth factor receptor 2 alterations","locally advanced cancer","cholangiocarcinoma","intrahepatic cholangiocarcinoma","unresectable cholangiocarcinoma","metastatic cholangiocarcinoma","fibroblast growth factor receptor inhibitor","2024-10-01",{"date":192,"type":32},"2024-10-03",{"date":194,"type":32},"2023-11-22",{"date":196,"type":21},"2027-09",{"name":38,"class":39},4,""]